Early Alzheimer's Disease Clinical Trial
— Clarity ADOfficial title:
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease
Verified date | June 2023 |
Source | Eisai Inc. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study will be conducted to evaluate the efficacy of lecanemab in participants with early Alzheimer's disease (EAD) by determining the superiority of lecanemab compared with placebo on the change from baseline in the Clinical Dementia Rating-Sum of Boxes (CDR-SB) at 18 months of treatment in the Core Study. This study will also evaluate the long-term safety and tolerability of lecanemab in participants with EAD in the Extension Phase and whether the long-term effects of lecanemab as measured by the CDR-SB at the end of the Core Study is maintained over time in the Extension Phase.
Status | Active, not recruiting |
Enrollment | 1906 |
Est. completion date | September 15, 2027 |
Est. primary completion date | September 15, 2027 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 50 Years to 90 Years |
Eligibility | Core Study: Inclusion Criteria Diagnosis: Mild Cognitive Impairment (MCI) due to Alzheimer's disease - intermediate likelihood: - Meet the National Institute of Aging - Alzheimer's Association (NIA-AA) core clinical criteria for MCI due to Alzheimer's disease - intermediate likelihood - Have a global Clinical Dementia Rating (CDR) score of 0.5 and CDR Memory Box score of 0.5 or greater at Screening and Baseline - Report a history of subjective memory decline with gradual onset and slow progression over the last 1 year before Screening; must be corroborated by an informant Mild Alzheimer's disease dementia: - Meet the NIA-AA core clinical criteria for probable Alzheimer's disease dementia - Have a global CDR score of 0.5 to 1.0 and a CDR Memory Box score of 0.5 or greater at Screening and Baseline Key Inclusion Criteria that must be met by all participants: - Objective impairment in episodic memory as indicated by at least 1 standard deviation below age-adjusted mean in the Wechsler Memory Scale IV-Logical Memory (subscale) II (WMS-IV LMII) - Positive biomarker for brain amyloid pathology - Male or female participants aged greater than or equal to (>=) 50 and less than or equal to (<=) 90 years, at the time of informed consent - Mini mental state examination (MMSE) score >=22 at Screening and Baseline and <=30 at Screening and Baseline - Body mass index (BMI) greater than (>)17 and less than (<) 35 at Screening - If receiving an approved Alzheimer's disease treatment such as acetylcholinesterase inhibitor (AChEIs) or memantine or both for Alzheimer's disease, must be on a stable dose for at least 12 weeks prior to Baseline. Treatment-naive participants for Alzheimer's disease can be entered into the study. Unless otherwise stated, participants must have been on stable doses of all other (that is, non-Alzheimer's disease-related) permitted concomitant medications for at least 4 weeks prior to Baseline. Use of memantine will not be allowed for participants in Japan - Have an identified study partner (defined as a person able to support the participant for the duration of the study and who spends at least 8 hours per week with the participant) - Provide written informed consent. If a participant lacks capacity to consent in the investigator's opinion, the participant's assent should be obtained, if required in accordance with local laws, regulations and customs, plus the written informed consent of a legal representative should be obtained (capacity to consent and definition of legal representative should be determined in accordance with applicable local laws and regulations). In countries where local laws, regulations, and customs do not permit participants who lack capacity to consent to participate in this study (example, Germany and Spain), they will not be enrolled Extension Phase: Inclusion Criteria: - Participants who have completed the Core Study (except de novo participants) - Must continue to have a study partner who is willing and able to provide follow-up information on the participant throughout the course of the Extension Phase - Provide written informed consent for the Extension Phase. If a participant lacks capacity to consent in the investigator's opinion, the participant's assent should be obtained, if required and in accordance with local laws, regulations and customs, plus the written informed consent of a legal representative should be obtained (capacity to consent and definition of legal representative should be determined in accordance with applicable local laws and regulations). In countries where local laws, regulations, and customs do not permit participants who lack capacity to consent to participate in this study (example, Germany and Spain), they will not be enrolled - Participants entering the subcutaneous (vial) substudy at Extension Phase Week 1, must be willing to participate, or continue participating in the amyloid positron emission tomography (PET) substudy. All participants must have an amyloid PET scan within 4 weeks before starting subcutaneous BAN2401. - Participants enrolling into the subcutaneous autoinjector substudy must have had at least 6 months exposure to BAN2401 10 mg/kg intravenously (IV) biweekly or BAN2401 720 mg subcutaneously (SC) weekly. Exclusion Criteria - Any neurological condition that may be contributing to cognitive impairment above and beyond that caused by the participant's Alzheimer's disease - History of transient ischemic attacks (TIA), stroke, or seizures within 12 months of Screening - Any psychiatric diagnosis or symptoms (example, hallucinations, major depression, or delusions) that could interfere with study procedures in the participant - Geriatric Depression Scale (GDS) score >=8 at Screening - Contraindications to MRI scanning, including cardiac pacemaker/defibrillator, ferromagnetic metal implants (example in skull and cardiac devices other than those approved as safe for use in MRI scanners) - Evidence of other clinically significant lesions on brain MRI at Screening that could indicate a dementia diagnosis other than Alzheimer's disease - Other significant pathological findings on brain MRI at screening, including but not limited to: more than 4 microhemorrhages (defined as 10 millimeter [mm] or less at the greatest diameter); a single macrohemorrhage >10 mm at greatest diameter; an area of superficial siderosis; evidence of vasogenic edema; evidence of cerebral contusion, encephalomalacia, aneurysms, vascular malformations, or infective lesions; evidence of multiple lacunar infarcts or stroke involving a major vascular territory, severe small vessel, or white matter disease; space occupying lesions; or brain tumors (however, lesions diagnosed as meningiomas or arachnoid cysts and <1 centimeter [cm] at their greatest diameter need not be exclusionary) - Any immunological disease which is not adequately controlled, or which requires treatment with immunoglobulins, systemic monoclonal antibodies (or derivatives of monoclonal antibodies), systemic immunosuppressants, or plasmapheresis during the study - Participants with a bleeding disorder that is not under adequate control (including a platelet count <50,000 or international normalized ratio [INR] >1.5 for participants who are not on anticoagulant treatment, example, warfarin). Participants who are on anticoagulant therapy should have their anticoagulant status optimized and be on a stable dose for 4 weeks before Screening. Participants who are on anticoagulant therapy are not permitted to participate in cerebrospinal fluid (CSF) assessments - Any other medical conditions (example, cardiac, respiratory, gastrointestinal, renal disease) which are not stably and adequately controlled, or which in the opinion of the investigator(s) could affect the participant's safety or interfere with the study assessments - Participation in a clinical study involving any therapeutic monoclonal antibody, protein derived from a monoclonal antibody, immunoglobulin therapy, or vaccine within 6 months before screening unless it can be documented that the participant was randomized to placebo - Participation in a clinical study involving any anti-amyloid therapies (including any monoclonal antibody therapies and any ß-site amyloid precursor protein cleaving enzyme [BACE] inhibitor therapies) unless it can be documented that the participant only received placebo - Participants who have any known prior exposure to lecanemab - Participants who were dosed in a clinical study involving any new chemical entities for AD within 6 months prior to screening unless it can be documented that the participant was in a placebo treatment arm Extension Phase: Exclusion Criteria - Participants who discontinued early from the Core Study - Participants who develop the following conditions from the time of Screening for the Core Study to the start of the Extension Phase - Any neurological condition that may be contributing to cognitive impairment above and beyond that caused by the participant's AD - Any psychiatric diagnosis or symptoms, (example, hallucinations, major depression, or delusions) that could interfere with study procedures in the participant - Contraindications to MRI scanning, including cardiac pacemaker/defibrillator, ferromagnetic metal implants (example, in skull and cardiac devices other than those approved as safe for use in MRI scanners) - Other significant pathological findings on brain MRI during the Core Study including but not limited to: cerebral contusion, encephalomalacia, aneurysms, vascular malformations, or infective lesions; evidence of multiple lacunar infarcts or stroke involving a major vascular territory, severe small vessel, or white matter disease; space occupying lesions; or brain tumors will be exclusionary if based on the opinion of the investigator, with consultation of medical monitor, these findings may interfere with the study procedures or safety - Hypersensitivity to BAN2401 or any of the excipients, or to any monoclonal antibody treatment - Any immunological disease which is not adequately controlled, or which requires chronic treatment with immunoglobulins, systemic monoclonal antibodies (or derivatives of monoclonal antibodies), systemic immunosuppressants, or plasmapheresis during the study - Any other clinically significant abnormalities in physical examination, vital signs, laboratory tests, or ECG, which in the opinion of the investigator require further investigation or treatment or which may interfere with study procedures or safety. - Malignant neoplasms (except for basal or squamous cell carcinoma in situ of the skin, or localized prostate cancer in male participants) that are not stably and adequately controlled or which, based on the opinion of the investigator, may interfere with the participant's safety or participation in the study - Any other medical conditions (example, cardiac, respiratory, gastrointestinal, renal disease) which are not stably and adequately controlled, or which in the opinion of the investigator(s) could affect the participant's safety or interfere with the study assessments - Severe visual or hearing impairment that would prevent the participant from performing psychometric tests accurately |
Country | Name | City | State |
---|---|---|---|
Australia | The Prince Charles Hospital/Internal Medicine & Dementia Research Unit | Chermside Brisbane | Queensland |
Australia | St Vincent's Hospital - Translational Research Centre | Darlinghurst | New South Wales |
Australia | Austin Health - Medical and Cognitive Research Unit | Ivanhoe | Victoria |
Australia | KaRa Institute of Neurological Diseases | Macquarie Park | New South Wales |
Australia | HammondCare Malvern Clinical Trials Unit | Malvern | Victoria |
Australia | Australian Alzheimer's Research Foundation | Nedlands | Western Australia |
Australia | Central Adelaide Local Health Network, The Queen Elizabeth Hospital and the Royal Adelaide Hospital | Woodville South, Adelaid | South Australia |
Canada | Recherches Neuro-Hippocampe Inc. d/b/a Clinique de la Mémoire de l'Outaouais | Gatineau | Quebec |
Canada | MoCA Clinic and Institute/NeuroSearch Developpements Inc. | Greenfield Park | Quebec |
Canada | True North Clinical Research Halifax, Inc. | Halifax | Nova Scotia |
Canada | Okanagan Clinical Trials | Kelowna | British Columbia |
Canada | True North Clinical Research Kentville, Inc. | Kentville | Nova Scotia |
Canada | St. Joseph's HC- Parkwood Institute | London | Ontario |
Canada | Recherches Neuro-Hippocampe, Inc., d/b/a Ottawa Memory Clinic | Ottawa | Ontario |
Canada | Kawartha Centre - Redefining Healthy Aging | Peterborough | Ontario |
Canada | Q&T Research Sherbrooke Inc. | Sherbrooke | Quebec |
Canada | Toronto Memory Program (Neurology Research Inc.) | Toronto | Ontario |
Canada | Health Research | West Vancouver | British Columbia |
China | Baotou Central Hospital | Baotou | Inner Mongolia Autonomous Region |
China | Beijing Friendship Hospital, Capital Medical University | Beijing | Beijing |
China | Beijing Tiantan Hospital, Capital Medical University | Beijing | Beijing |
China | Xuanwu Hospital Capital Medical University | Beijing | Beijing |
China | The First Bethune Hospital of Jilin University | Changchun | Jilin |
China | Xiangya Hospital Central South University | Changsha | Hunan |
China | Guangdong Provincial People's Hospital | Guangzhou | Guangzhou |
China | Guangzhou First People's Hospital | Guangzhou | Guangdong |
China | Guangzhou Huiai Hospital | Guangzhou | Guangdong |
China | Sun Yat-Sent Memorial Hospital of Sun Yat-Sen University | Guangzhou | Guangdong |
China | Sir Run Run Shaw Hospital, Zhejiang University School of Medicine | Hangzhou | Zhejiang |
China | Jinan Central Hospital | Jinan | Shandong |
China | Nanjing Brain Hospital, Affiliated to Nanjing Medical University | Nanjing | Jiangsu |
China | Nanjing Drum Tower Hospital | Nanjing | Jiangsu |
China | Renji Hospital Shanghai Jiaotong Universtiy School of Medicine | Shanghai | Shanghai |
China | Shanghai Sixth People's Hospital | Shanghai | Shanghai |
China | Shanghai Tongji Hospital | Shanghai | Shanghai |
China | The Second Hospital of Hebei Medical University | Shijiazhuang | Hebei |
China | Tianjin Huanhu Hospital | Tianjin | Tianjin |
China | Qinghai Provincial People's Hospital | Xining | Qinghai |
China | Henan Provincial People's Hospital | Zhengzhou | Henan |
France | Hôpital neurologique Pierre Wertheimer | Bron Cedex | |
France | Hopital de la Timone | Marseille | Cedex 05 |
France | Hôpital Gui de Chauliac | Montpellier | Cedex 5 |
France | Hopital Guillaume et Renà LaÃnnec | Nantes | Cedex |
France | Groupe Hospitalier Pitie-Salpetriere | Paris | Cedex |
France | Hôpital Lariboisière | Paris cedex 10 | Paris |
France | Hôpital de Hautepierre | Strasbourg Cedex | Bas Rhin |
France | Centre de Recherche Clinique du Gérontopôle | Toulouse | Haute Garonne |
Germany | Eisai Trial Site #6 | Berlin | |
Germany | Eisai Trial Site #1 | Bielefeld | |
Germany | Eisai Trial Site #4 | Erbach | |
Germany | Eisai Trial Site #5 | Günzburg | Baden Wuerttemberg |
Germany | Eisai Trial Site #2 | Mannheim | Baden-Wurttemberg |
Germany | Eisai Trial Site #3 | Munchen | |
Italy | Fondazione Istituto G.Giglio di Cefalù | Cefalu | Palermo |
Italy | Clinica Neurologica, IRCCS Ospedale Policlinico San Martino, Genova | Genova | |
Italy | Fondazione IRCCS CA' Granda Ospedale Maggiore Policlinico - U.O.S.D. Malattie Neurodegenerative | Milano | |
Italy | ASST-Monza, Ospedale San Gerardo | Monza | |
Italy | Prima Clinica Neurologica, Primo Policlinico AOU "L. Vanvitelli" | Napoli | |
Italy | Ospedale S. Maria della Misericordia, S. Andrea delle Fratte | Perugia | |
Italy | Azienda Ospedaliero Universitaria Pisana | Pisa | |
Italy | Fondazione Policlinico Agostino Gemelli - UCSC | Roma | |
Italy | Universita' Sapienza di Roma - Dipartimento di Neuroscienze Umane | Roma | |
Italy | Ospedale "Card. G. Panico" - | Tricase | LE |
Japan | Eisai Trial Site #7 | Atsugi-shi | Kanagawa |
Japan | Eisai Trial Site #29 | Bunkyo-ku | Tokyo |
Japan | Eisai Trial Site #5 | Bunkyo-ku | Tokyo |
Japan | Eisai Trial Site #15 | Chiba-shi | Chiba |
Japan | Eisai Trial Site #1 | Fujioka-shi | Gunma |
Japan | Eisai Trial Site #17 | Fujisawa-shi | Kanagawa |
Japan | Eisai Trial Site #13 | Hachioji-shi | Tokyo |
Japan | Eisai Trial Site #33 | Higashimorokatagun | Miyazaki |
Japan | Eisai Trial Site #28 | Himeji-shi | Hyogo |
Japan | Eisai Trial Site #8 | Hirakata | Osaka |
Japan | Eisai Trial Site #21 | Hofu | Yamaguchi |
Japan | Eisai Trial Site #9 | Kahoku | Ishikawa |
Japan | Eisai Trial Site #20 | Kawasaki-shi | Kanagawa |
Japan | Eisai Trial Site #19 | Kobe-shi | Hyogo |
Japan | Eisai Trial Site #16 | Kurashiki-shi | Okayama |
Japan | Eisai Trial Site #12 | Musashino-shi | Tokyo |
Japan | Eisai Trial Site #22 | Niigata-shi | Niigata |
Japan | Eisai Trial Site #4 | Obu-shi | Aichi |
Japan | Eisai Trial Site #11 | Osaka | |
Japan | Eisai Trial Site #27 | Osaka | |
Japan | Eisai Trial Site #32 | Otake | Hiroshima |
Japan | Eisai Trial Site #31 | Otsu-shi | Shiga |
Japan | Eisai Trial Site #18 | Saitama-shi | Saitama |
Japan | Eisai Trial Site #30 | Sapporo-shi | Hokkaido |
Japan | Eisai Trial Site #23 | Shinagawa-ku | Tokyo |
Japan | Eisai Trial Site #10 | Shinjuku-ku | Tokyo |
Japan | Eisai Trial Site #25 | Shinjuku-ku | Tokyo |
Japan | Eisai Trial Site #26 | Suita-shi | Osaka |
Japan | Eisai Trial Site #24 | Toride-shi | Ibaraki |
Japan | Eisai Trial Site #14 | Ube-shi | Yamaguchi |
Japan | Eisai Trial Site #3 | Yamagata-shi | Yamagata |
Japan | Eisai Trial Site #2 | Yokohama-shi | Kanagawa |
Japan | Eisai Trial Site #6 | Yoshida-gun | Fukui |
Korea, Republic of | Dong-A University Hospital | Busan | |
Korea, Republic of | Chonnam National University Hospital | Gwangju | Jeolla-do |
Korea, Republic of | Inha University Hospital | Incheon | |
Korea, Republic of | Seoul National University Bundang Hospital | Seongnam | Gyeonggi-do |
Korea, Republic of | Seoul National University Bundang Hospital | Seongnam-si | Seoul |
Korea, Republic of | Asan Medical Center | Seoul | |
Korea, Republic of | Hanyang University Seoul Hospital | Seoul | |
Korea, Republic of | Konkuk University Medical Center | Seoul | |
Korea, Republic of | Samsung Medical Center | Seoul | |
Korea, Republic of | Seoul National University Boramae Medical Center | Seoul | |
Korea, Republic of | Seoul National University Hospital | Seoul | |
Korea, Republic of | Severance Hospital, Yonsei University Health System | Seoul | |
Korea, Republic of | The Catholic University of Korea, Seoul ST. Mary's Hospital | Seoul | |
Russian Federation | First Moscow State Medical University n.a. I.M. Sechenov | Moscow | |
Singapore | National University Hospital | Singapore | |
Spain | Fundacion ACE, Barcelona | Barcelona | |
Spain | Hospital Clinic i Provincial de Barcelona | Barcelona | |
Spain | Hospital Santa Cruz y San Pablo | Barcelona | |
Spain | Hospital Universitario Reina Sofía | Cordoba | |
Spain | Fundación CITA-alzheimer Findazioa | Donostia San Sebastian | Gipuzkoa |
Spain | Centro CAE Oroitu | Getxo | Bizkaia |
Spain | Complejo Hospitalario Ruber Juan Bravo | Madrid | |
Spain | Hospital de Salamanca | Salamanca | |
Spain | Policlinica Guipuzcoa | San Sebastian | Guipuzcoa |
Spain | Hospital General de Catalunya | Sant Cugat del Valles | Barcelona |
Spain | Hospital Victoria Eugenia - Cruz Roja | Sevilla | |
Spain | Hospital Universitari i Politècnic La Fe | Valencia | |
Sweden | Sahlgrenska University Hospital | Gothenburg | Västra Götalandslän |
Sweden | Memory Clinic, Malmö University Hospital | Malmö | |
Sweden | Karolinska University Hospital | Stockholm | |
Sweden | Uppsala University Hospital, Uppsala | Uppsala | |
United Kingdom | Re:Cognition Health Ltd | Birmingham | |
United Kingdom | Re:Cognition Health Ltd | Guildford | |
United Kingdom | Charing Cross Hospital | London | |
United Kingdom | Re:Cognition Health Ltd | London | |
United Kingdom | St. Pancras Clinical Research | London | |
United Kingdom | Re:Cognition Health | Plymouth | Devon |
United Kingdom | Sheffield Memory Service | Sheffield | South Yorkshire |
United Kingdom | Memory Assessment & Research Centre (MARC), | Southampton | Hampshire |
United States | Albany Medical College | Albany | New York |
United States | Neurological Associates of Albany, PC | Albany | New York |
United States | Emory University Cognitive Neurology Clinic & ADRC | Atlanta | Georgia |
United States | JEM Research Institute | Atlantis | Florida |
United States | Senior Adult Specialty Research | Austin | Texas |
United States | Partners Population Health | Belmont | Massachusetts |
United States | DBA The Memory Clinic | Bennington | Vermont |
United States | Brigham and Women's Hospital | Boston | Massachusetts |
United States | Bradenton Research Center, Inc. | Bradenton | Florida |
United States | OH Clinical Research Partners | Canton | Ohio |
United States | ImmunoE Research Center | Centennial | Colorado |
United States | ANI Neurology, PLLC d/b/a Alzheimer's Memory Center | Charlotte | North Carolina |
United States | Great Lakes Clinical Trials | Chicago | Illinois |
United States | Cleveland Clinic | Cleveland | Ohio |
United States | Columbs Neuroscience, LLC | Columbus | Ohio |
United States | Columbus Memory Center | Columbus | Georgia |
United States | Ohio State University | Columbus | Ohio |
United States | Advanced Clinical Research Network | Coral Gables | Florida |
United States | Linfritz Research Institute, Inc. | Coral Gables | Florida |
United States | Neurology Clinic, P.C. | Cordova | Tennessee |
United States | Kerwin Research Center | Dallas | Texas |
United States | Texas Neurology, PA | Dallas | Texas |
United States | iResearch Atlanta, LLC | Decatur | Georgia |
United States | NeuroStudies.net, LLC | Decatur | Georgia |
United States | Brain Matters Research | Delray Beach | Florida |
United States | Mile High Research Center | Denver | Colorado |
United States | Rhode Island Mood & Memory Research Institute | East Providence | Rhode Island |
United States | Associated Neurologists of Southern Connecticut | Fairfield | Connecticut |
United States | Neuropsychiatric Research Center of Southwest FL | Fort Myers | Florida |
United States | Fort Wayne Neurological Center | Fort Wayne | Indiana |
United States | Neurology Center of North Orange County | Fullerton | California |
United States | Hattiesburg Clinic | Hattiesburg | Mississippi |
United States | Infinity Clinical Research | Hollywood | Florida |
United States | Hawaii Pacific Neuroscience | Honolulu | Hawaii |
United States | Baylor College of Medicine AD and Memory Disorders Center | Houston | Texas |
United States | Clinical Trial Network | Houston | Texas |
United States | Indiana University School of Medicine | Indianapolis | Indiana |
United States | Irvine Clinical Research | Irvine | California |
United States | University of Kansas Medical Center Research Institute | Kansas City | Kansas |
United States | Alliance for Multispecialty Research LLC, New Orleans Center for Clinical Research / Volunteer Research Group, an AMR company | Knoxville | Tennessee |
United States | Charter Research | Lady Lake | Florida |
United States | Alzheimer's Research and Treatment Center | Lake Worth | Florida |
United States | Cleveland Clinic Lou Ruvo Center for Brain Health | Las Vegas | Nevada |
United States | Las Vegas Medical Research | Las Vegas | Nevada |
United States | University of California - Los Angeles | Los Angeles | California |
United States | Clincloud, LLC | Maitland | Florida |
United States | ActivMed Practices & Research | Methuen | Massachusetts |
United States | Allied Biomedical Research (Clinical Trial) | Miami | Florida |
United States | BioMed Research Institute | Miami | Florida |
United States | CCM Clinical Research Group | Miami | Florida |
United States | Finlay Medical Research | Miami | Florida |
United States | Gonzalez MD & Aswad MD Health Services | Miami | Florida |
United States | Miami Jewish Health Systems | Miami | Florida |
United States | Pharmax Research of South Florida, Inc | Miami | Florida |
United States | Rios Medical Center, Inc. | Miami | Florida |
United States | Visionary Investigators Network | Miami | Florida |
United States | Visionary Investigators Network | Miami | Florida |
United States | Vitae Research Center | Miami | Florida |
United States | Galiz Research | Miami Springs | Florida |
United States | Institute for Neurodegenerative Disorders | New Haven | Connecticut |
United States | Yale University School Of Medicine | New Haven | Connecticut |
United States | Neurological Institute of New York | New York | New York |
United States | New York University Medical Center PRIME | New York | New York |
United States | Boston Center for Memory | Newton | Massachusetts |
United States | Keystone Clinical Studies, LLC | Norristown | Pennsylvania |
United States | Roper St. Francis Healthcare | North Charleston | South Carolina |
United States | Research Center for Clinical Studies, Inc. | Norwalk | Connecticut |
United States | Renstar Medical Research | Ocala | Florida |
United States | Lynn Health Science Institute | Oklahoma City | Oklahoma |
United States | Bioclinica Research | Orlando | Florida |
United States | Neurology Associates of Ormond Beach | Ormond Beach | Florida |
United States | Pacific Neuroscience Medical Group | Oxnard | California |
United States | Advanced Research Consultants, Inc. | Palm Beach Gardens | Florida |
United States | IMIC, Inc. | Palmetto Bay | Florida |
United States | Stanford University Medical Center | Palo Alto | California |
United States | Advocate Lutheran General Hospital | Park Ridge | Illinois |
United States | University of Pennsylvania | Philadelphia | Pennsylvania |
United States | Banner Alzheimer's Institute- Clinical Trials Department | Phoenix | Arizona |
United States | Donald S. Marks, MD. P.C. | Plymouth | Massachusetts |
United States | Quantum Laboratories Inc. | Pompano Beach | Florida |
United States | Neurostudies, Inc. | Port Charlotte | Florida |
United States | Progressive Medical Research | Port Orange | Florida |
United States | Coastal Neurology, P.A. | Port Royal | South Carolina |
United States | Neural Net Research, LLC | Portland | Oregon |
United States | Oregon Health & Science University | Portland | Oregon |
United States | Summit Research Network (OR) Inc. | Portland | Oregon |
United States | Butler Hospital - Memory and Aging Program | Providence | Rhode Island |
United States | Rhode Island Hospital | Providence | Rhode Island |
United States | Raleigh Neurology Associates, P.A. - Research Department | Raleigh | North Carolina |
United States | National Clinical Research Inc.-Richmond | Richmond | Virginia |
United States | University of Rochester | Rochester | New York |
United States | Washington University | Saint Louis | Missouri |
United States | Pacific Research Network, Inc | San Diego | California |
United States | Sharp Mesa Vista Hospital | San Diego | California |
United States | UCSF Memory and Aging Center | San Francisco | California |
United States | Apex Research Institute | Santa Ana | California |
United States | St Joseph Heritage Healthcare | Santa Rosa | California |
United States | North Bay Neuroscience Research Institute | Sebastopol | California |
United States | Kingfisher Cooperative LLC | Spokane | Washington |
United States | Alzheimer's Research and Treatment Center | Stuart | Florida |
United States | Banner Sun Health Research | Sun City | Arizona |
United States | Infinity Clinical Research, LLC | Sunrise | Florida |
United States | Stedman Clinical Trials, LLC | Tampa | Florida |
United States | USF Suncoast Gerontology Center | Tampa | Florida |
United States | Bioclinica Research | The Villages | Florida |
United States | Advanced Memory Research Institute of NJ, PC | Toms River | New Jersey |
United States | Bio Behavioral Health | Toms River | New Jersey |
United States | Neurological Associates of Tucson dba Center for Neurosciences | Tucson | Arizona |
United States | Georgetown University Hospital | Washington | District of Columbia |
United States | Premiere Research Institute, West Palm | West Palm Beach | Florida |
United States | KU Wichita Center for Clinical Research | Wichita | Kansas |
United States | PMG Research of Winston Salem | Winston-Salem | North Carolina |
Lead Sponsor | Collaborator |
---|---|
Eisai Inc. | Biogen |
United States, Australia, Canada, China, France, Germany, Italy, Japan, Korea, Republic of, Russian Federation, Singapore, Spain, Sweden, United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Core Study: Change from Baseline in the CDR-SB at 18 Months | Baseline, 18 months | ||
Primary | Extension Phase: Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs) | A TEAE is defined as an adverse event that emerges during treatment or within 30 days of the last dose of study drug, having been absent at pretreatment (Baseline) or reemerges during treatment, having been present at pretreatment (Baseline) but stopped before treatment, or worsens in severity during treatment relative to the pretreatment state, when the adverse event was continuous. Number of participants with TEAEs (serious and non-serious adverse events) were reported based on their regular measurement of vital signs, safety assessments of laboratory tests, antidrug antibody assessments, suicidality assessments, magnetic resonance imaging and electrocardiogram parameter values. | From first dose of study drug up to approximately 51 months (including 3 months follow up) for the extension phase | |
Primary | Extension Phase: Change from Core Study Baseline in CDR-SB | Baseline up to Month 69 | ||
Secondary | Core Phase: Change From Baseline in Amyloid Positron Emission Tomography (PET) Using Centiloids at 18 Months | Baseline, 18 months | ||
Secondary | Core Study: Change from Baseline in Alzheimer Disease Assessment Scale - Cognitive Subscale 14 (ADAS-cog14) at 18 Months | Baseline, 18 months | ||
Secondary | Core Phase: Change From Baseline in Alzheimer's Disease Composite Score (ADCOMS) at 18 Months | Baseline, 18 months | ||
Secondary | Core Study: Change From Baseline in Alzheimer's Disease Cooperative Study-Activities of Daily Living Scale for Mild Cognitive Impairment (ADCS MCI-ADL) at 18 Months | Baseline, 18 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT04693520 -
Biomarker Effects of ALZ-801 in APOE4 Carriers With Early Alzheimer's Disease
|
Phase 2 | |
Recruiting |
NCT05122598 -
Development and Evaluation of Computerized Olfactory Training Program for Cognitive Decline in Early Alzheimer's Disease
|
Phase 2 | |
Active, not recruiting |
NCT04770220 -
An Efficacy and Safety Study of ALZ-801 in APOE4/4 Early AD Subjects
|
Phase 3 | |
Active, not recruiting |
NCT04777396 -
A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE)
|
Phase 3 | |
Recruiting |
NCT05531656 -
A Study to Evaluate the Safety and Efficacy of CT1812 in Early Alzheimer's Disease
|
Phase 2 | |
Recruiting |
NCT04599764 -
High Definition Transcranial Direct Current Stimulation (HD-tDCS) for Early Alzheimer's Disease
|
N/A | |
Completed |
NCT05161715 -
Proof-of-concept, Open-label Study in Patients With Early Alzheimer's Disease
|
Phase 2 | |
Completed |
NCT02859207 -
A Study to Evaluate the Pharmacokinetics of E2609 and Its Metabolites in Subjects With Mild and Moderate Hepatic Impairment Compared With Healthy Subjects
|
Phase 1 | |
Enrolling by invitation |
NCT06304883 -
Long-term Extension of Phase 3 Study of ALZ- 801 in APOE4/4 Early AD Subjects
|
Phase 3 |